|
Of Mice and Mets
Yes, it is a question of balancing risks and benefits. But in the case of DCA, where the risks have already been established in patients and it is FDA approved for other purposes, I hope to goodness the tests are done on the newly diagnosed so that we don't miss the boat entirely on this one just because we "always" test patients with mets first instead of patients who correlate to the mice, whose cells have never been compromised by other therapies first.
AlaskaAngel
|